JP2016508992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508992A5 JP2016508992A5 JP2015552890A JP2015552890A JP2016508992A5 JP 2016508992 A5 JP2016508992 A5 JP 2016508992A5 JP 2015552890 A JP2015552890 A JP 2015552890A JP 2015552890 A JP2015552890 A JP 2015552890A JP 2016508992 A5 JP2016508992 A5 JP 2016508992A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- gastroretentive
- form according
- hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006186 oral dosage form Substances 0.000 claims 29
- 230000002496 gastric effect Effects 0.000 claims 15
- 230000014759 maintenance of location Effects 0.000 claims 13
- 229920000642 polymer Polymers 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims 6
- 239000002516 radical scavenger Substances 0.000 claims 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 5
- 239000003613 bile acid Substances 0.000 claims 5
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 229920001484 poly(alkylene) Polymers 0.000 claims 3
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims 2
- 229920002905 Colesevelam Polymers 0.000 claims 2
- 239000008351 acetate buffer Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010063655 Erosive oesophagitis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010030201 Oesophageal ulcer Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229960001152 colesevelam Drugs 0.000 claims 1
- 229960000674 colesevelam hydrochloride Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000028299 esophageal disease Diseases 0.000 claims 1
- 208000019064 esophageal ulcer Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000005980 lung dysfunction Effects 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752726P | 2013-01-15 | 2013-01-15 | |
| US61/752,726 | 2013-01-15 | ||
| US201361914804P | 2013-12-11 | 2013-12-11 | |
| US61/914,804 | 2013-12-11 | ||
| PCT/US2014/011450 WO2014113377A1 (en) | 2013-01-15 | 2014-01-14 | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189952A Division JP6755920B2 (ja) | 2013-01-15 | 2018-10-05 | 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508992A JP2016508992A (ja) | 2016-03-24 |
| JP2016508992A5 true JP2016508992A5 (https=) | 2017-02-23 |
| JP6716255B2 JP6716255B2 (ja) | 2020-07-01 |
Family
ID=50031605
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552890A Expired - Fee Related JP6716255B2 (ja) | 2013-01-15 | 2014-01-14 | 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形 |
| JP2018189952A Expired - Fee Related JP6755920B2 (ja) | 2013-01-15 | 2018-10-05 | 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189952A Expired - Fee Related JP6755920B2 (ja) | 2013-01-15 | 2018-10-05 | 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20160015644A1 (https=) |
| EP (2) | EP3991719A1 (https=) |
| JP (2) | JP6716255B2 (https=) |
| CN (2) | CN105338958A (https=) |
| AU (1) | AU2014207680B2 (https=) |
| BR (1) | BR112015016917B1 (https=) |
| CA (1) | CA2898362C (https=) |
| EA (1) | EA201591338A1 (https=) |
| ES (1) | ES2906114T3 (https=) |
| MX (1) | MX383752B (https=) |
| WO (1) | WO2014113377A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2898362C (en) * | 2013-01-15 | 2020-09-01 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
| WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| US20180015118A1 (en) | 2015-02-03 | 2018-01-18 | Ironwood Pharmaceuticals, Inc. | Methods of treating upper gastrointestinal disorders in ppi refractory gerd |
| CN105362244A (zh) * | 2015-11-26 | 2016-03-02 | 青岛海之源智能技术有限公司 | 考来烯胺缓释片及制备方法 |
| CN105456219A (zh) * | 2015-12-28 | 2016-04-06 | 青岛海之星生物科技有限公司 | 一种考来替泊缓释片及制备方法 |
| CN105520919A (zh) * | 2015-12-28 | 2016-04-27 | 青岛海之星生物科技有限公司 | 一种考来替泊缓释胶囊及制备方法 |
| MX2019007574A (es) * | 2016-12-21 | 2019-09-04 | Ironwood Pharmaceuticals Inc | Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida. |
| JP2020527580A (ja) * | 2017-07-19 | 2020-09-10 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 胃滞留性胆汁酸捕捉剤剤形の有効性 |
| EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
| CN111110647A (zh) * | 2018-10-31 | 2020-05-08 | 浙江京新药业股份有限公司 | 含盐酸考来维仑的药物组合物及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS5692217A (en) | 1979-12-26 | 1981-07-25 | Kowa Co | Easily absorbable enzyme preparation |
| US4359465A (en) | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| US4472409A (en) | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
| AU545463B2 (en) | 1982-06-25 | 1985-07-18 | Kowa Co. Ltd. | Benzoyl piperacine esters |
| SE8300736D0 (sv) | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| JPS59222484A (ja) | 1983-06-02 | 1984-12-14 | Kowa Co | テトラヒドロナフチルカルボン酸フエニルエステル誘導体 |
| JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| US4738975A (en) | 1985-07-02 | 1988-04-19 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, and use as anti-ulcer agents |
| CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| FI96860C (fi) | 1987-06-17 | 1996-09-10 | Eisai Co Ltd | Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi |
| JP2916205B2 (ja) | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
| JP2916206B2 (ja) | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
| DK223790D0 (da) | 1990-09-18 | 1990-09-18 | Novo Nordisk As | Proteaseholdig detergentkomposition |
| US5312824A (en) | 1990-10-17 | 1994-05-17 | Takeda Chemical Industries, Ltd. | Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers |
| US5167483A (en) | 1990-12-24 | 1992-12-01 | Gardiner Samuel W | Method for utilizing angular momentum in energy conversion devices and an apparatus therefore |
| YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| US5877192A (en) | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| EP2124884B1 (en) * | 2006-12-22 | 2019-07-10 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| WO2009158625A2 (en) * | 2008-06-26 | 2009-12-30 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
| US20100008988A1 (en) * | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
| CA2898362C (en) * | 2013-01-15 | 2020-09-01 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
| CN103585128A (zh) * | 2013-11-18 | 2014-02-19 | 北京泰德制药股份有限公司 | 一种包含盐酸考来维仑的药物组合物及其制备方法 |
-
2014
- 2014-01-14 CA CA2898362A patent/CA2898362C/en active Active
- 2014-01-14 CN CN201480015783.9A patent/CN105338958A/zh active Pending
- 2014-01-14 EP EP21202140.6A patent/EP3991719A1/en not_active Withdrawn
- 2014-01-14 EP EP14702387.3A patent/EP2945614B1/en not_active Not-in-force
- 2014-01-14 CN CN201711090819.1A patent/CN108057028A/zh active Pending
- 2014-01-14 WO PCT/US2014/011450 patent/WO2014113377A1/en not_active Ceased
- 2014-01-14 JP JP2015552890A patent/JP6716255B2/ja not_active Expired - Fee Related
- 2014-01-14 ES ES14702387T patent/ES2906114T3/es active Active
- 2014-01-14 EA EA201591338A patent/EA201591338A1/ru unknown
- 2014-01-14 MX MX2015009055A patent/MX383752B/es unknown
- 2014-01-14 BR BR112015016917-1A patent/BR112015016917B1/pt not_active IP Right Cessation
- 2014-01-14 US US14/760,883 patent/US20160015644A1/en not_active Abandoned
- 2014-01-14 AU AU2014207680A patent/AU2014207680B2/en not_active Ceased
-
2017
- 2017-02-27 US US15/443,747 patent/US20170266116A1/en not_active Abandoned
-
2018
- 2018-10-05 JP JP2018189952A patent/JP6755920B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-30 US US17/039,662 patent/US20210015754A1/en not_active Abandoned
-
2021
- 2021-05-07 US US17/314,213 patent/US20210267903A1/en not_active Abandoned
- 2021-12-20 US US17/556,210 patent/US20220110876A1/en not_active Abandoned
-
2022
- 2022-08-05 US US17/881,714 patent/US20220370367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508992A5 (https=) | ||
| Maradey-Romero et al. | New and future drug development for gastroesophageal reflux disease | |
| US20220370367A1 (en) | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | |
| JP2005508358A5 (https=) | ||
| Yusif et al. | Gastroretentive matrix tablets of boswellia oleogum resin: preparation, optimization, in vitro evaluation, and cytoprotective effect on indomethacin-induced gastric ulcer in rabbits | |
| JP2020527580A5 (https=) | ||
| CA2901166C (en) | Enteric coated tablet | |
| KR101648490B1 (ko) | 위체류 약물 전달시스템을 이용한 서방성 경구용 제제 | |
| Kadian et al. | Eudragit and its pharmaceutical significance | |
| JP2016513693A (ja) | 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物 | |
| US20230248758A1 (en) | Methods of treating upper gastrointestinal disorders in ppi refractory gerd | |
| CN107224585B (zh) | 一种包含非甾体抗炎药和质子泵抑制剂的组合物 | |
| CN104116739B (zh) | 一种含多潘立酮的药物组合物 | |
| CN107496392B (zh) | 姜黄素在制备治疗胃食管反流病的药物上的应用 | |
| RU2021117507A (ru) | Фармацевтические композиции акотиамида и ингибитора протонной помпы | |
| Madan et al. | Formulation and evaluation of a bilayer floating drug delivery system of nizatidine for nocturnal acid breakthrough | |
| Zerbib et al. | W1085 Clinical Efficacy and Tolerability of Monotherapy With ADX10059, a mGluR5 Negative Allosteric Modulator, for Symptom Control in Patients With Gastro-Esophageal Reflux Disease (GERD) | |
| BALOFLOXACIN | International Journal of Pharmacy | |
| Reddy | Preparation and Evaluation of Controlled Release Gastric Floating Drug Delivery System of Proton Pump Inhibitor | |
| EA202090331A1 (ru) | Эффективность удерживаемой в желудке лекарственной формы секвестрантов желчных кислот | |
| Yoshida et al. | W1084 Rebamipide Protects Against Recurrence of Symptoms of Gastroesophageal Reflux Disease: Synergistic Effect of Rebamipide With 15mg Lansoprazole | |
| HK1214529B (en) | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |